Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
The effectiveness and retention rates of methotrexate in psoriatic arthritis with methotrexate treated patients with rheumatoid arthritis as a reference population
Annals of Rheumatic Diseases, 09/22/09
Lie E et al. – MTX treatment was associated with improvement of disease activity and health related quality of life in PsA patients after 6 months of therapy. Retention rates of MTX were similar in PsA and RA
Methods- Data on 430 PsA patients participating in an ongoing longitudinal observational multicenter study
- 1218 MTX naïve rheumatoid arthritis (RA) patients from the same study served as a reference population
- Assessments included measures of disease activity (28-joint counts, acute phase reactants), health status and utility scores
- 6-month effectiveness data were compared both by crude analyses and with adjustments for age, sex and the respective baseline values
- After 6 months of MTX treatment, both PsA and RA patients improved in most disease activity measures and patient reported outcomes
- In the adjusted analysis PsA patients tended to have less improvement, but changes were in the same range as in RA patients
- Two-year retention rates of MTX therapy in PsA and RA patients were 65% and 66%, respectively, with only minor differences in reported reasons for discontinuation
- Lower age, longer disease duration, and higher MHAQ score and patient global assessment were independent predictors of MTX termination within the first two years of treatment
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: Clinicopathological features of 24 patients
Journal of Rheumatology, 11/09/09
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09
Today in Other Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Hepatoprotective effect of TNF-alpha blockade in psoriatic arthritis: A cross-sectional study
Annals of Rheumatic Diseases, 11/09/09
The use of complementary and alternative medicine in outpatients with inflammatory rheumatic diseases in Sweden
Scandinavian Journal of Rheumatology , 11/17/09
Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis
Rheumatology International, 10/26/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment of polymyalgia rheumatica
Archives of Internal Medicine, 11/10/09
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09
Sponsor
Article Search
Sponsor


See Latest Articles


